Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AveXis Enters Mfg. Pact for Novel Genetic COVID-19 Vax | Contract Pharma

What are you searching for?

Sign in
Breaking News

AveXis Enters Mfg. Pact for Novel Genetic COVID-19 Vax

AAVCOVID, being developed by U.S. researchers in Massachusetts, leverages adeno-associated viral vector technology to produce immunity.

By: Contract Pharma

Contract Pharma Staff

AveXis, Novartis’s gene therapy unit, has signed a manufacturing agreement to produce a novel genetic COVID-19 vaccine candidate, AAVCOVID, being developed by U.S. researchers in Massachusetts.

Massachusetts General Hospital and Massachusetts Eye and Ear are developing a vaccine candidate leveraging adeno-associated viral (AAV) vector technology to produce immunity. The vaccine is in preclinical development with human trials expected in 2020 to determine safety and efficacy.

AveXis is contributing technology, expertise and manufacturing supply chain at no cost, according to the company.

“The COVID-19 pandemic is the most urgent public health crisis of our time and we recognize the significance of evaluating the potential role of a gene-based vaccine,” said AveXis President Dave Lennon, adding his company’s experience producing one of just two commercial gene therapies on the market makes it “uniquely poised to help the team move quickly toward this accelerated effort.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics